Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

A Phase 2 Trial of SCRI-CAR19 Demonstrates Favorable Leukemia-Free Survival (LFS), with a Pilot Study of CD19-Expressing T-Cell Antigen Presenting Cells (CD19t T-APCs) Demonstrating Safety and Tolerability

Colleen Annesley, Kristy Seidel, Qian Vicky Wu, Corinne Summers, Alan S. Wayne, Anurag K. Agrawal, Michael A. Pulsipher, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Ashley L. Wilson, Wenjun Huang, Julie R. Park, Michael C. Jensen, Rebecca A. Gardner

Blood (2023) 142 (Supplement 1): 3467.

https://doi.org/10.1182/blood-2023-190525

Published: 2023

Journal Articles

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

Colleen Annesley, Corinne Summers, Michael A. Pulsipher, Jodi L. Skiles, Amanda M. Li, Anant Vatsayan, Catherine Lindgren, Stephanie Mgebroff, Ashley Wilson, Wenjun Huang, Qian Vicky Wu, Josh Gustafson, Christopher Brown, Michael C. Jensen, Julie R. Park, Rebecca A Gardner

Blood (2021) 138 (Supplement 1): 470.

https://doi.org/10.1182/blood-2021-148881

Published: 2021

Journal Articles

Poor Clinical Outcome in Pediatric Immunotherapy Is Mediated By a Pre-Existing Overactive IL-18-IFNy Immune Phenotype

Katelyn Burleigh, Anna Kus, Alice Long, Michael C. Jensen, Seth Masters, James E Vince, Bobbie-Jo Webb-Robertson, Rebecca A Gardner, Heather Gustafson

Blood (2021) 138 (Supplement 1): 168.

https://doi.org/10.1182/blood-2021-148013

Published: 2021

Journal Articles

CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04

Corinne Summers, Blake Baxter, Colleen Annesley, Jason Yokoyama, Stephanie Rhea, Wenjun Huang, Ashley Wilson, Julie R. Park, Rimas J Orentas, Michael C. Jensen, Rebecca A Gardner

Blood (2021) 138 (Supplement 1): 403.

https://doi.org/10.1182/blood-2021-147928

Published: 2021

Journal Articles

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner, Francesco Ceppi, Julie Rivers, Colleen Annesley, Corinne Summers, Agne Taraseviciute, Juliane Gust, Kasey J. Leger, Katherine Tarlock, Todd M. Cooper, Olivia C. Finney, Hannah Brakke, Daniel H. Li, Julie R. Park, Michael C. Jensen

Blood (2019) 134 (24): 2149–2158.

https://doi.org/10.1182/blood.2019001463

Published: 2019

Includes: Supplemental data

Journal Articles

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Colleen Annesley, MD, Rebecca Gardner, MD, Ashley Wilson, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Qian Vicky Wu, PhD, Adam Brand, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2019) 134 (Supplement_1): 223.

https://doi.org/10.1182/blood-2019-131346

Published: 2019

Journal Articles

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Jacob Appelbaum, MD PhD, Anisha Loeb, BA, Kelda Gardner, PA-C, Carole M. Shaw, BA, Paul C. Hendrie, MD PhD, Colin D. Godwin, MDMPhil, Mary-Elizabeth M. Percival, MD, Anna B. Halpern, MD, Bart L. Scott, MD, Vivian G. Oehler, MD, Roland B. Walter, MD PhD MS, Pamela S. Becker, MD PhD, Michael C. Jensen, MD, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 260.

https://doi.org/10.1182/blood-2019-131678

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance

Katherine Elizabeth Masih, BS, Rebecca Gardner, MD, Berkley Gryder, PhD, Abdelmaksoud Abdallah, BS, Justin Lack, PhD, Benjamin Stanton, PhD, Ashley Wilson, PhD, Sivasish Sindiri, MS, Young Song, PhD, Zachary Rae, BS, Michael Kelly, PhD, Wang Chaoyu, MS, Xinyu Wen, MS, Adam Cheuk, PhD, Jun Wei, PhD, Michael C. Jensen, MD, Javed Khan, MD, Rimas Orentas, PhD

Blood (2019) 134 (Supplement_1): 2744.

https://doi.org/10.1182/blood-2019-130796

Published: 2019

Journal Articles

Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

Francesco Ceppi, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Stephanie Rhea, BS, Isaac C. Jenkins, MS, Qian V. Wu, PhD, Wen Yang, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie R. Park, MD, Rebecca Gardner, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2018-99-110164

Published: 2018

Journal Articles

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Colleen Annesley, MD, Rebecca Gardner, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4021.

https://doi.org/10.1182/blood-2018-99-112285

Published: 2018

Journal Articles

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Brakke, MS, Stephanie Rhea, BS, Roxana Hicks, BS, Danielle Doolittle, Marisa Lopez, Rimas J Orentas, PhD, Daniel Li, PhD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4022.

https://doi.org/10.1182/blood-2018-99-117493

Published: 2018

Journal Articles

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Rebecca Gardner, MD, Colleen Annesley, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Kaelin Crews, Lauren Huang, Christopher Brown, Stephanie Mgebroff, Catherine Lindgren, Karen Spratt, PhD, Josh Gustafson, PhD, Adam Johnson, PhD, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 278.

https://doi.org/10.1182/blood-2018-99-113126

Published: 2018

Journal Articles

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

Corinne Summers, MD, Colleen Annesley, MD, Marie Bleakley, MBBS, PhD MMSc, Ann Dahlberg, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2018) 132 (Supplement 1): 967.

https://doi.org/10.1182/blood-2018-99-115599

Published: 2018

Journal Articles

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells

Julie Rivers, MD, Colleen Annesley, MD, Corinne Summers, MD, Olivia Finney, PhD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2018) 132 (Supplement 1): 2957.

https://doi.org/10.1182/blood-2018-99-113744

Published: 2018

Journal Articles

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Rebecca A. Gardner, Olivia Finney, Colleen Annesley, Hannah Brakke, Corinne Summers, Kasey Leger, Marie Bleakley, Christopher Brown, Stephanie Mgebroff, Karen S. Kelly-Spratt, Virginia Hoglund, Catherine Lindgren, Assaf P. Oron, Daniel Li, Stanley R. Riddell, Julie R. Park, Michael C. Jensen

Blood (2017) 129 (25): 3322–3331.

https://doi.org/10.1182/blood-2017-02-769208

Published: 2017

Includes: Supplemental data

Journal Articles

Multiplexed Engineering of CD19CAR T Cells for Post-Transplant Consolidative Immunotherapy

Corinne Summers, MD, Alexandra Grier, Rebecca Gardner, MD, Colleen Delaney, MD MSc, Michael C Jensen, MD

Blood (2016) 128 (22): 1159.

https://doi.org/10.1182/blood.V128.22.1159.1159

Published: 2016

Journal Articles

Creation of the First Non-Human Primate Model That Faithfully Recapitulates Chimeric Antigen Receptor (CAR) T Cell-Mediated Cytokine Release Syndrome (CRS) and Neurologic Toxicity Following B Cell-Directed CAR-T Cell Therapy

Agne Taraseviciute, MD PhD, Leslie Kean, MD PhD, Michael C Jensen, MD

Blood (2016) 128 (22): 651.

https://doi.org/10.1182/blood.V128.22.651.651

Published: 2016

Journal Articles

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Rebecca Gardner, MD, Olivia Finney, PhD, Hannah Smithers, MS, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Christopher Brown, Stephanie Mgebroff, MS, Catherine Lindgren, Karen Spratt, PhD, Assaf Oron, PhD, Daniel Li, PhD, Marie Bleakley, MDPhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 219.

https://doi.org/10.1182/blood.V128.22.219.219

Published: 2016

Journal Articles

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Rebecca Gardner, MD, Kasey J Leger, MD MSc, Colleen E. Annesley, MD, Corinne Summers, MD, Julie Rivers, MD, Juliane Gust, MD, Katherine Tarlock, MD, Todd M Cooper, DO, Navin R. Pinto, MD, Olivia Finney, PhD, Hannah Smithers, MS, Assaf Oron, PhD, Daniel Li, PhD, Julie R Park, MD, Michael C Jensen, MD

Blood (2016) 128 (22): 586.

https://doi.org/10.1182/blood.V128.22.586.586

Published: 2016

NARROW

A Phase 2 Trial of SCRI-CAR19 Demonstrates Favorable Leukemia-Free Survival (LFS), with a Pilot Study of CD19-Expressing T-Cell Antigen Presenting Cells (CD19t T-APCs) Demonstrating Safety and Tolerability

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

Poor Clinical Outcome in Pediatric Immunotherapy Is Mediated By a Pre-Existing Overactive IL-18-IFNy Immune Phenotype

CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Additional Cytotoxic Chemotherapy Is Unlikely to Eliminate Measurable Residual Acute Myeloid Leukemia (AML)

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Detailed Multi-Method Analysis of Bone Marrow from Pediatric Pre-B-ALL Patients Prior to CD19-CAR-T Therapy Subsequently Evidencing Overt CAR-T Resistance

Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Starting T Cell and Cell Product Phenotype Are Associated with Durable Remission of Leukemia Following CD19 CAR-T Cell Immunotherapy

Early Clinical Experience of CD19 x CD22 Dual Specific CAR T Cells for Enhanced Anti-Leukemic Targeting of Acute Lymphoblastic Leukemia

Long Term Follow-up after SCRI-CAR19v1 Reveals Late Recurrences As Well As a Survival Advantage to Consolidation with HCT after CAR T Cell Induced Remission

Early Response Data for Pediatric Patients with Non-Hodgkin Lymphoma Treated with CD19 Chimeric Antigen Receptor (CAR) T-Cells

Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults

Multiplexed Engineering of CD19CAR T Cells for Post-Transplant Consolidative Immunotherapy

Creation of the First Non-Human Primate Model That Faithfully Recapitulates Chimeric Antigen Receptor (CAR) T Cell-Mediated Cytokine Release Syndrome (CRS) and Neurologic Toxicity Following B Cell-Directed CAR-T Cell Therapy

CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL

Decreased Rates of Severe CRS Seen with Early Intervention Strategies for CD19 CAR-T Cell Toxicity Management

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only